47 research outputs found

    Conditional quantitative trait locus mapping of wheat seed protein-fraction in relation to starch content

    Get PDF
    Protein and starch are important in wheat quality and yield. To understand the genetic relationship between protein and starch at the quantitative trait locus (QTL)/gene level, 168 doubled haploid (DH) lines were used at three locations over 2 years. The QTLs for proteinfraction contents and starch content were analyzed by unconditional and conditional QTL mapping. We detected 17 unconditional additive QTLs (four albumin QTLs, three globulin QTLs, six gliadin QTLs, four glutenin QTLs) controlling protein-fraction contents. We detected 19 conditional QTLs (five albumin QTLs, three globulin QTLs, five gliadin QTLs, six glutenin QTLs) based on starch content. Of these QTLs, QAlu1B, QGlo6A, QGli1B, QGli7A, QGlu1B and QGlu1D increased the protein-fraction contents independent of the starch content. These QTLs could regulate the usual inverse relationship between protein and starch in wheat seeds. The results could possibly be used in the simultaneous improvement of grain protein and starch content in wheat breeding

    Partial Wave Analysis of J/ψγ(K+Kπ+π)J/\psi \to \gamma (K^+K^-\pi^+\pi^-)

    Full text link
    BES data on J/ψγ(K+Kπ+π)J/\psi \to \gamma (K^+K^-\pi^+\pi^-) are presented. The KKˉK^*\bar K^* contribution peaks strongly near threshold. It is fitted with a broad 0+0^{-+} resonance with mass M=1800±100M = 1800 \pm 100 MeV, width Γ=500±200\Gamma = 500 \pm 200 MeV. A broad 2++2^{++} resonance peaking at 2020 MeV is also required with width 500\sim 500 MeV. There is further evidence for a 2+2^{-+} component peaking at 2.55 GeV. The non-KKˉK^*\bar K^* contribution is close to phase space; it peaks at 2.6 GeV and is very different from KKˉK^{*}\bar{K^{*}}.Comment: 15 pages, 6 figures, 1 table, Submitted to PL

    Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

    Get PDF
    BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

    Production of Υ(nS) mesons in Pb+Pb and pp collisions at 5.02 TeV

    Get PDF
    A measurement of the production of vector bottomonium states, Υ ( 1S ) , Υ ( 2S ) , and Υ ( 3S ) , in Pb + Pb and p p collisions at a center-of-mass energy per nucleon pair of 5.02 TeV is presented. The data correspond to integrated luminosities of 1.38 nb − 1 of Pb + Pb data collected in 2018, 0.44 nb − 1 of Pb + Pb data collected in 2015, and 0.26 fb − 1 of p p data collected in 2017 by the ATLAS detector at the Large Hadron Collider. The measurements are performed in the dimuon decay channel for transverse momentum p μ μ T &lt; 30 GeV , absolute rapidity | y μ μ | &lt; 1.5 , and Pb + Pb event centrality 0–80%. The production rates of the three bottomonium states in Pb + Pb collisions are compared with those in p p collisions to extract the nuclear modification factors as functions of event centrality, p μ μ T , and | y μ μ | . In addition, the suppression of the excited states relative to the ground state is studied. The results are compared with theoretical model calculations

    Dynamic equivalents of distribution systems for voltage stability studies

    No full text

    Study on Attitude Measurement System for Virtual Surgery Navigation

    No full text
    corecore